FACTORS AFFECTING THERAPEUTIC DRUG MONITORING

Slides:



Advertisements
Similar presentations
Connecting Pharmacology with Therapeutics Clive Roberts.
Advertisements

DISPOSITION OF DRUGS The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill,
III. Drug Metabolism  The aim of drug metabolism is to convert lipid soluble (non polar) drugs to polar metabolites easily excreted in urine.  The liver.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
New Zealand College of Pharmacists
Yasar Kucukardali Professor, Internal Medicine Yeditepe University.
Pharmacokinetics: Bioavailability Asmah Nasser, M.D.
Dose Adjustment in Renal and Hepatic Disease
CHAPTER 2 Pharmacologic Principles Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Clinical Pharmacokinetics. Clinical Pharmacodynamics. Drugs’ Interaction. Adverse Effects of Drugs.
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption
Biotransformation and metabolism
Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 8 Individual Variation in Drug Responses.
Bioavailability Dr Mohammad Issa.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
PHARMACOKINETICS Part 3.
VARIABILITY IN PHARMACOKINETICS & PATIENT RESPONSE Dr. Mohd B. Makmor Bakry, Ph.D., RPh Senior Lecturer in Clinical Pharmacy Universiti Kebangsaan Malaysia.
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
INTRODUCTION CLINICAL PHARMACOKINETICS
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
TDM Therapeutic Drug Monitoring
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Therapeutic drug Monitoring
DRUG TREATMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC RENAL DISEASE Presented by Ri.
PHT 415 BASIC PHARMACOKINETICS
Pharmacokinetics 2 General Pharmacology M212
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
Foundation Knowledge and Skills
METABOLISME DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA dr. Yunita Sari Pane.
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
INTRODUCTION TO PHARMACOKINETICS M. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague, Charles University in Prague,
PHARMACOKINETICS ABSORPTION →DISTRIBUTION→METABOLISM→EXCRETION Chapter 26 – Fundamentals NUR 152 Denise Turner, MS-N.Ed, CCRN, RN.
Pharmacology I Session One Pharmacological Principles.
Clinical Chemistry and the Geriatric patient
Drug Therapy in Geriatric Patients
Cyclosporine.
Drug Metabolism Drugs are most often eliminated by biotransformation and/or excretion into the urine or bile. The process of metabolism transforms lipophilic.
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Anticonvulsants: Valproic acid
Quantitative Pharmacokinetics
Pharmaceutics 2.
Drug Therapy in Pediatric Patients
Biopharmaceutics Dr Mohammad Issa Saleh.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Pharmacologic Principles – Chapter 2
Pharmacokinetics and Factors of Individual Variation
Foundations and Principles of Pharmacology
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Selected Bioavailability and Pharmacokinetic Calculations
Clinical Pharmacokinetics
1 Concentration-time curve
Basic Biopharmaceutics
Therapeutic Drug Monitoring chapter 1 part 1
Foundations and Principles of Pharmacology
Biopharmaceutics and pharmacokinetic by: Anjam Hama A. M. Sc
BIOAVAILABILITY.
Pharmacologic Principles
Therapeutic Drug Monitoring
Medication Administration for Pediatrics
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
POLYPHARMACY.
Presentation transcript:

FACTORS AFFECTING THERAPEUTIC DRUG MONITORING

INTRODUCTION Therapeutic drug monitoring (TDM) is generally defined as the clinical laboratory measurement of a chemical parameter that, with appropriate medical interpretation, will directly influence drug prescribing procedures by combining knowledge of pharmaceutics, pharmacokinetics, and pharmacodynamics.

CLINICAL USEFULNESS OF TDM Maximize efficacy of drug Avoiding toxicity Identifying therapeutic failure Facilitating dose adjustment Facilitating therapeutic effects

Factors Affecting TDM 1. Patient demographics 2. Patient Compliance 3. Individuals capacity to absorb/distribute/metabolize/excrete the drug 4. Genetic factors

Factors Affecting TDM… 5. Concomitant disease, Tropical disease and nutritional deficiencies 6. Alternative system of medicine 7. Ethnic differences and extrapolation of the normal range

Factors Affecting TDM… 8. Alcohol & Tobacco use 9. Quality of medication and generic formulation 10. Control of drug assay 11. Medication or sampling errors 12. Laboratory errors 13. Cost effectiveness

1. Patient demographics Age, sex and lean body weight are particularly important for renally cleared drugs as knowledge of these allows calculation of creatinine clearance.

2. Patient Compliance If the concentration of the drug is lower than expected, the possibility of non compliance should be considered before a dose increase is recommended.

3. Individuals capacity to absorb/distribute/metabolize/excrete the drug Absorption: The rate of absorption and extent of absorption are dependent on various factors such as: Drug formulation Manufacturer Route of administration Intra-individual variations Another aspect of absorption is bioavailability. This is the fraction of the administered dose that reaches the systemic circulation. Bioavailability is 100% for IV injection.

Distribution: (Vd) = dose/plasma concentration The absolute bioavailability of a drug. For example if a drug has a half life of four hours, four hours after the initial dose, 50% of the drug will be removed. Eight hours after the initial dose, half of the remaining drug (25% of total) will be removed, for a total of 75% having been removed at that time, and so on. Half-life information is used to determine the correct drug dose required to attain the desired therapeutic range

Metabolism: In addition, drug metabolites can be either protein bound (inactive) or free (active). The drug dosage will depend on how the drug metabolizes. Factors that impact drug metabolism includes genetics, environment, nutrition, and age.

Excretion: Drug excretion from the body occurs through the kidneys, or fluids excreted through the lungs, GI or skin. Renal dysfunction reduces drug clearance and may contribute to drug accumulation and increased risk of adverse drug effects.

Some other causes Age: In general, drugs metabolized more slowly in foetal, neonatal, and geriatric populations Physical properties of the drug (hydrophobicity, pKa, solubility) If the drug is administered in a fed or fasted state Gastric emptying rate

Interactions with other drugs (e.g. antacids, alcohol, nicotine) Interactions with other foods.

Enzyme induction/inhibition by other drugs/foods:- Enzyme induction (increase rate of metabolism). e.g. Phenytoin, barbiturates, carbamazepine, glutethimide, primidone, rifampicin induces CYP1A2, CYP2C9, CYP2C19 and CYP3A4, , which is involved in a drug's metabolism may reduce the drug's activity Enzyme inhibition (decrease rate of metabolism), resulting in ↑ drug activity, e.g. Protease inhibitors, Nitrogen mustard, Mtx, Cidenafil Citrate

Drug Interactions TDM results should be interpreted in light of the patients other drug therapy For example: patient on digoxin may have unexpected high digoxin serum concentration and develop digoxin toxicity if drug such as verapamil are started without a reduction in digoxin dose. The serum concentration of some hepatically cleared drugs may be affected by cessation of drugs with either induce or inhibit hepatic cytochrome P450 isoenzymes.

5. Concomitant disease, Tropical disease and nutritional deficiencies This includes diseases highly prevalent in developing countries such as Infections, Diarrhoea, Worm infestations, Tuberculosis, Nutritional deficiencies, plus a Higher proportion of patients with diabetes and AIDS

6. Alternative system of medicine India is unique in having at least three systems of medicine coexisting with ‘western’ medicine (allopathy); ayurveda, homeopathy and unani. A patient with a history of generalized tonic-clonic (GTC) seizures, well controlled and with plasma phenytoin levels within the therapeutic range, presented with sudden loss of seizure control.

8. Alcohol & Tobacco use Chronic use of alcohol has been shown to cause non-specific hepatic microsomal enzyme induction, resulting in increased clearance and decreased serum concentrations of hepatically cleared drugs. Cigarette smoking increases the hepatic clearance of theophylline and patients who have recently stopped smoking may have unexpectedly high theophylline concentrations

9. Medication or sampling errors In cases where the TDM result is incompatible with drug administration records, the possibility of a medication or sampling error should be considered. For Example, the drug may have been given to the wrong patient, or blood may have been mistakenly drawn from a patient in a neighbouring bed.

10. Laboratory errors If a laboratory error is suspected, the laboratory should be contacted and asked to repeat the assay. Alternatively, a new blood sample can be drawn and sent to a different laboratory for assay.

11. Cost effectiveness Rapid and cost-effective measurement of most drugs for which TDM is indicated can be achieved using commercial kits run on automated analysers using a number of different methodologies including fluorescence polarisation immunoassay. 

Testing Methodologies In HPLC liquid containing sample is injected at one end of the column. high pressure is used to overcome resistance to flow As liquid flows some molecule move faster than others due to diff in solubility. The exact time for each molecule to flow through the column is measured by detector. The retention time is calculated. An internal standard compound similar in structure to the specimen to be analyzed is also run through the column. By comparing retention time of sample and standard molecule can be identified. Concentration of drug can also be determine that peak produce during run.

THANK YOU -PHARMA STREET